Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6855
Gene Symbol: SYP
SYP
0.010 AlteredExpression disease BEFREE In addition to cytokeratin, synaptophysin and glial fibrillary acidic protein expression, PTPR were examined for the presence of dot- or ring-like epithelial membrane antigen (EMA) immunoreactivity typically encountered in ependymoma, staining for inwardly rectifying potassium channel Kir7.1 and stanniocalcin-1 (specifically expressed in choroid plexus tumours) as well as microtubule-associated protein-2 (MAP-2). 16640646 2006
Entrez Id: 2670
Gene Symbol: GFAP
GFAP
0.010 AlteredExpression disease BEFREE In addition to cytokeratin, synaptophysin and glial fibrillary acidic protein expression, PTPR were examined for the presence of dot- or ring-like epithelial membrane antigen (EMA) immunoreactivity typically encountered in ependymoma, staining for inwardly rectifying potassium channel Kir7.1 and stanniocalcin-1 (specifically expressed in choroid plexus tumours) as well as microtubule-associated protein-2 (MAP-2). 16640646 2006
Entrez Id: 4133
Gene Symbol: MAP2
MAP2
0.010 AlteredExpression disease BEFREE In addition to cytokeratin, synaptophysin and glial fibrillary acidic protein expression, PTPR were examined for the presence of dot- or ring-like epithelial membrane antigen (EMA) immunoreactivity typically encountered in ependymoma, staining for inwardly rectifying potassium channel Kir7.1 and stanniocalcin-1 (specifically expressed in choroid plexus tumours) as well as microtubule-associated protein-2 (MAP-2). 16640646 2006
Entrez Id: 6781
Gene Symbol: STC1
STC1
0.010 Biomarker disease BEFREE In addition to cytokeratin, synaptophysin and glial fibrillary acidic protein expression, PTPR were examined for the presence of dot- or ring-like epithelial membrane antigen (EMA) immunoreactivity typically encountered in ependymoma, staining for inwardly rectifying potassium channel Kir7.1 and stanniocalcin-1 (specifically expressed in choroid plexus tumours) as well as microtubule-associated protein-2 (MAP-2). 16640646 2006
Entrez Id: 324
Gene Symbol: APC
APC
0.010 GeneticVariation disease BEFREE In summary, although inherited APC mutations may be associated with ependymoma development in certain TS2 cases, these data indicate that somatic mutations affecting APC and CTNNB1 do not play a major role in the pathogenesis of sporadic ependymomas. 16843107 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.030 Biomarker disease BEFREE Methylation of p16 (INK4A), p14 (ARF), TIMP3, CDH1, p15 (INK4B )and DAPK1 in medulloblastoma (MB) and ependymoma has been discussed controversially in the literature. 17206475 2007
Entrez Id: 1030
Gene Symbol: CDKN2B
CDKN2B
0.020 Biomarker disease BEFREE Methylation of p16 (INK4A), p14 (ARF), TIMP3, CDH1, p15 (INK4B )and DAPK1 in medulloblastoma (MB) and ependymoma has been discussed controversially in the literature. 17206475 2007
Entrez Id: 1612
Gene Symbol: DAPK1
DAPK1
0.010 Biomarker disease BEFREE Methylation of p16 (INK4A), p14 (ARF), TIMP3, CDH1, p15 (INK4B )and DAPK1 in medulloblastoma (MB) and ependymoma has been discussed controversially in the literature. 17206475 2007
Entrez Id: 828
Gene Symbol: CAPS
CAPS
0.010 Biomarker disease BEFREE Calcyphosine immunoreactivity was observed in 59% of the ependymomas and was most profound in ependymoma tissue showing epithelial differentiation. mRNA expression levels of stathmin, annexin A1, and calcyphosine significantly correlated (Rs = 0.65 [p < 0.0001], Rs = 0.50 [p = 0.001], and Rs = 0.72 [p < 0.0001], respectively) with protein expression levels. 17549010 2007
Entrez Id: 3925
Gene Symbol: STMN1
STMN1
0.010 AlteredExpression disease BEFREE Calcyphosine immunoreactivity was observed in 59% of the ependymomas and was most profound in ependymoma tissue showing epithelial differentiation. mRNA expression levels of stathmin, annexin A1, and calcyphosine significantly correlated (Rs = 0.65 [p < 0.0001], Rs = 0.50 [p = 0.001], and Rs = 0.72 [p < 0.0001], respectively) with protein expression levels. 17549010 2007
Entrez Id: 27165
Gene Symbol: GLS2
GLS2
0.010 AlteredExpression disease BEFREE LGA mRNA expression was relatively very low in cultured astrocytes, and very low to absent in astrocytoma pilocyticum, ependymoma and subependymal giant cell astrocytoma (SEGA), tumors of astrocytic origin. 17940881 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.050 AlteredExpression disease BEFREE We evaluated the tyrosine kinase inhibitor gefitinib for its antitumor activity and potential to radio-sensitize in vivo in two xenograft models: an EGFR amplified glioma and an EGFR expressing ependymoma, both derived from primary tumors. 18386816 2008
Entrez Id: 6659
Gene Symbol: SOX4
SOX4
0.010 AlteredExpression disease BEFREE Both SOX4 and SOX11 were significantly overexpressed in medulloblastoma (median, 11-fold and 5-fold, respectively) compared with ependymoma and normal cerebellum. 18577562 2008
Entrez Id: 6662
Gene Symbol: SOX9
SOX9
0.010 AlteredExpression disease BEFREE SOX9 expression was predictive for favorable outcome in ependymoma. 18577562 2008
Entrez Id: 6664
Gene Symbol: SOX11
SOX11
0.010 AlteredExpression disease BEFREE Both SOX4 and SOX11 were significantly overexpressed in medulloblastoma (median, 11-fold and 5-fold, respectively) compared with ependymoma and normal cerebellum. 18577562 2008
Entrez Id: 5880
Gene Symbol: RAC2
RAC2
0.010 AlteredExpression disease BEFREE Loss of one or more of the genes on 22 was detected in 81% of cases, with RAC2 and C22ORF2 at 22q12-q13.1 being deleted most frequently in 38% and 32% of ependymoma samples, respectively. 18663750 2008
Entrez Id: 25776
Gene Symbol: CBY1
CBY1
0.010 AlteredExpression disease BEFREE Combined analysis of quantitative-PCR with methylation-specific PCR and bisulphite sequencing revealed a high rate (>60% ependymoma) of transcriptional inactivation of C22ORF2, indicating its potential importance in the development of pediatric ependymomas. 18663750 2008
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.070 GeneticVariation disease BEFREE Recurrent paediatric supratentorial extraventricular ependymoma associated with genetic mutation at exon 4 of p53 gene. 18695856 2008
Entrez Id: 6275
Gene Symbol: S100A4
S100A4
0.010 AlteredExpression disease BEFREE In conclusion, this study provides evidence that S100A6 and S100A4 are differentially expressed in clinically relevant subgroups, and also demonstrates a link between CHI3L1 protein expression and necrosis in intracranial paediatric ependymoma. 18781180 2008
Entrez Id: 6277
Gene Symbol: S100A6
S100A6
0.010 AlteredExpression disease BEFREE In conclusion, this study provides evidence that S100A6 and S100A4 are differentially expressed in clinically relevant subgroups, and also demonstrates a link between CHI3L1 protein expression and necrosis in intracranial paediatric ependymoma. 18781180 2008
Entrez Id: 1116
Gene Symbol: CHI3L1
CHI3L1
0.010 AlteredExpression disease BEFREE In conclusion, this study provides evidence that S100A6 and S100A4 are differentially expressed in clinically relevant subgroups, and also demonstrates a link between CHI3L1 protein expression and necrosis in intracranial paediatric ependymoma. 18781180 2008
Entrez Id: 6285
Gene Symbol: S100B
S100B
0.010 AlteredExpression disease BEFREE Moreover, three more members of the S100 family had distinct gene expression profiles in ependymoma. 18781180 2008
Entrez Id: 6271
Gene Symbol: S100A1
S100A1
0.010 AlteredExpression disease BEFREE Moreover, three more members of the S100 family had distinct gene expression profiles in ependymoma. 18781180 2008
Entrez Id: 6273
Gene Symbol: S100A2
S100A2
0.010 Biomarker disease BEFREE Candidates (CHI3L1, S100A10, S100A4, S100A6 and S100A2) were validated using immunohistochemistry on a tissue microarray of 74 paediatric ependymoma. 18781180 2008
Entrez Id: 3371
Gene Symbol: TNC
TNC
0.020 Biomarker disease BEFREE The activation of the Notch pathway and Tenascin-C seem to be important events in ependymoma progression and may represent future targets for therapy. 19289631 2009